

DATE	ACTION/DESCRIPTION
07/23/2018	New policy for Sublocade created.
08/24/2022	Annual Review. Transferred to new template. Updated references. Updated initial approval duration to 6 months. Clarified reauthorization criteria.
07/20/2023	Policy name changed to Buprenorphine extended-release (Sublocade, Brixadi); Brixadi added to policy; removed DATA waiver prescriber requirement; added references; added an age limit, added trial of preferred buprenorphine product; added medical benefit option.

References:

1. Sublocade [package insert]. North Chesterfield, VA: Indivior, Inc; August 2022.
2. Brixadi [package insert]. Cockeysville, MD: Pharmaceutics International, Inc; May 2023.
3. White L, et al. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020 Mar/Apr;14(2S Suppl 1):1-91.
4. Center for Substance Abuse Treatment. Clinical guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.

Effective date: 01/01/2024

Revised date: 07/20/2023